Conference Coverage

The amount of patients being diagnosed with neurological conditions and multiple sclerosis (MS) is a growing number, which causes a need for more neurologists, MS specialists, and better access to care. A potential advantage of using technology in MS care would be to break down the geographic barrier. To learn more about telehealth in MS care, tune in with Dr. Marisa McGinley, Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, who also presented this topic at the ACTRIMS Forum 2024.

A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.

If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.

Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for Veterans with Advanced Prostate Cancer” session at the 2024 ASCO Genitourinary Cancers Symposium.

The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.

Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.

Inflammatory breast cancer (IBC) is a rare disease that represents about two to three percent of all breast cancers and is challenging to diagnose. To improve diagnosis, researchers are working to validate a new proposed scoring system. Review the current research with Dr. Flipia Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.

It’s very common for patients with inflammatory breast cancer (IBC) to present with no underlying palpable mass, which may cause some challenges for clinicians and patients. So what are some unique challenges associated with surgery in IBC and the risks of deescalating? Join Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School, as she reviews her research on IBC that she presented at the 2023 San Antonio Breast Cancer Symposium.

Invasive lobular carcinoma (ILC) is an understudied subtype that occurs in about 10 to 15 percent of breast cancer patients and is known to be difficult to detect by imaging. So how do we approach diagnosing and treating this subtype? Dr. Pavani Chalasani is joined by Dr. Jason Mouabbi, Assistant Professor of Medicine at the University of Texas MD Anderson Cancer Center and Chair of the Lobular Breast Cancer Alliance, to discuss his session on ILC at the 2023 San Antonio Breast Cancer Symposium.

According to a Gallup poll, Generation Z youth identify as LGBTQ more than previous generations. Given this increasing prevalence, clinicians need to know how to foster synergistic relationships between parents and LGBTQ+ youth. Here to discuss this important topic is Dr. Dalmacio Dennis Flores, an Assistant Professor at the University of Pennsylvania School of Nursing. He also spoke about this exact topic at the 2023 Annual ANAC conference in his session, titled “Synergy in Inclusive Sexual Health: Triadic Models Empowering LGBTQ+ Youth, Parents, and Nurses.”